TEVIMBRA’s Continued Success - BeiGene Expands Its PD-1...

ha aggiunto una foto Health

2025-08-18 14:26:57 -

TEVIMBRA’s Continued Success - BeiGene Expands Its PD-1 Indication

BeiGene’s PD-1 inhibitor, TEVIMBRA, is gaining momentum in oncology with a newly secured indication, reinforcing its position in the competitive esophageal squamous cell carcinoma market. The recent approval in the UK highlights BeiGene’s growing influence beyond Asia. With this advancement, TEVIMBRA (tislelizumab) is further establishing itself as a strong alternative to existing...

0 Commenti 0 condivisioni 38 Views 0 Anteprima